Hyperbaric oxygen has no established role in chronic tinnitus — the Cochrane review recommends against it for that purpose — and only a narrow, time-limited place as an option in sudden hearing loss.
Hyperbaric oxygen therapy is a real medical treatment with a real, narrow role in ear medicine, and that role is not tinnitus. The distinction between where it works and where it is sold is unusually sharp here, and unusually easy to state.
The one sentence that settles it
The Cochrane review on hyperbaric oxygen for sudden hearing loss and tinnitus ends with this:
From the sourceThere is no evidence of a beneficial effect of HBOT on chronic ISSHL or tinnitus and we do not recommend the use of HBOT for this purpose.
That is a systematic review of the exact question, reaching a direct recommendation against. Very little in tinnitus is stated that plainly.
Where the evidence does point somewhere
The same review found something for a different condition, and the difference is what matters.
For acute idiopathic sudden sensorineural hearing loss — the time-critical emergency covered in sudden sensorineural hearing loss — seven trials with 392 participants produced a real but qualified signal. HBOT did not significantly improve the chance of a 50% recovery in hearing threshold (risk ratio 1.53, 95% CI 0.85 to 2.78). It did improve the chance of a 25% recovery (risk ratio 1.39, 95% CI 1.05 to 1.84), a 22% greater chance of improvement, with a number needed to treat of 5. Average pure-tone threshold came out 15.6 dB better.
Three caveats travel with those numbers, and the reviewers state all three: the studies were small and generally of poor quality, the clinical significance of the improvement remains unclear, and an appropriately powered trial is still justified to work out which patients, if any, benefit most.
And on tinnitus specifically, even within those acute trials: the significance of any improvement in tinnitus could not be assessed by pooled analysis. Not "no effect" — no analysable data.
What the guideline permits, exactly
The American Academy of Otolaryngology–Head and Neck Surgery's sudden hearing loss guideline places HBOT among its options — the weakest of its three tiers, below recommendations — in two specific circumstances:
- Combined with steroid therapy, within two weeks of the onset of sudden sensorineural hearing loss.
- Combined with steroid therapy as salvage therapy, within one month of onset.
Read the shape of that rather than just the permission. It is bounded by a condition (sudden hearing loss, not tinnitus), a companion treatment (steroids, not HBOT alone), and a clock (two weeks, or one month for salvage). Chronic tinnitus fails all three tests.
The same guideline makes a strong recommendation that patients left with residual hearing loss or tinnitus be counselled about audiologic rehabilitation and supportive measures — which is where someone in that position is meant to be directed.
The risk that comes with it
Hyperbaric oxygen is generally regarded as a low-risk treatment, but pressurising the body pressurises the middle ear, and middle ear barotrauma is its main side effect. A five-year review of 2,610 patients at a hyperbaric centre in Marseille found 262 had experienced it, a prevalence of about 10%. Most cases were at the mild end of the grading scale, but barotrauma was responsible for people stopping treatment early. Older age, being female, a history of ear, nose and throat problems, and sudden deafness as the reason for treatment were among the risk factors it identified.
For someone treated within the sudden hearing loss window, that is a known risk weighed against a possible hearing benefit. For chronic tinnitus it is an ear risk accepted for an ear complaint with no expected benefit.
Why this gets sold anyway
The mechanism is plausible, which is the usual reason a treatment outlives its evidence. HBOT raises dissolved oxygen in the blood, the cochlea has a demanding blood supply, and a treatment that improves oxygen delivery to the inner ear is a reasonable thing to try. The Cochrane review opens with exactly that rationale.
Plausible mechanism and demonstrated benefit are different things. The articles on ginkgo, PEMF and laser therapy each describe a version of the same gap.
What is unusual here is that the plausible mechanism did produce a signal — in the acute condition, under a clock. The marketing keeps the signal and drops the conditions.
What to do
- If your hearing dropped suddenly, within the last two weeks, get urgent medical care; HBOT is a legitimate conversation to have alongside steroids, not instead of them. The timing there is the whole thing, and steroid treatment, including steroid injections through the eardrum, is the core of treatment.
- If your tinnitus is chronic, there is nothing here for you, and the review says so directly rather than leaving it to inference.
- If a clinic offers HBOT for tinnitus, the question that sorts it is which condition and when it started. A course means repeated sessions in a chamber, with the barotrauma risk above, for a use the evidence does not support.